Skip to main content
. 2022 Mar 19;22:292. doi: 10.1186/s12885-022-09397-4

Fig. 2.

Fig. 2

Long-term health outcomes associated to testing-ROS1 and to no-testing ROS1 strategies, base case. a Health outcomes expressed in total PF-LYs and total LYs; b Health outcomes expressed in total QALYs. ROS1: c-ros oncogene 1; PF:Progression-free life years; LY: life years; QALY: quality-adjusted life years